Mx-1 conditionally immortalized cells

• US 6,495,364 B2
• Filed: 03/07/2001
• Issued: 12/17/2002
• Est. Priority Date: 05/23/1995
• Status: Expired due to Fees

• Current Assignee: Neurotech USA, Inc. (Woodbrook Group Holdings, Inc.)
• Original Assignee: Neurotech S.A. (LivaNova Plc)
• Inventors: Messing, Albee, Hammang, Joseph P.
• Primary Examiner(s): NGUYEN, DAVE TRONG
• Application Number:
  US09/801,237
• Publication Number:
  US 20010043923A1
• Time in Patent Office: 650 Days
• Field of Search: 435/320.1, 435/455, 435/325, 514/44, 424/93.2
• US Class Current: 435/320.1
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61L 27/383 Nerve cells, e.g. dendritic cells, Schwann cells
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: C12N 2510/04 Immortalised cells

Abstract

This invention relates to methods and compositions of controlling cell distribution within a bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the BAO with ECM molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination.

Claims

1. An isolated expression vector comprising a proliferation-promoting gene and an Mx-1 promoter operably linked to the proliferation-promoting gene.

2. The vector of claim 1, wherein the proliferation-promoting gene is SV40 large T antigen or c-myc.